Previous or current malignancies at other sites, with the exception of adequately treated in situ carcinoma of the cervix, basal or squamous cell carcinoma of the skin, thyroid cancer, or other cancer curatively treated by surgery and with no current evidence of disease for at least  years
Previous or current malignancies at other sites, with the exception of adequately treated in situ carcinoma of the cervix, basal or squamous cell carcinoma of the skin, thyroid cancer, or other cancer curatively treated by surgery and with no current evidence of disease for at least  years
Current malignancies of another type, with the exception of adequately treated in situ cervical cancer and basal cell skin cancer, squamous cell carcinoma of the skin or other malignancies with no evidence of disease for  years or more.
History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last  years.
Patients with prior malignancies within the last  years except resected basal cell carcinoma or treated cervical carcinoma in situ
Current malignancies of another type, with the exception of adequately treated in situ cervical cancer and basal cell skin cancer or other malignancies with no evidence of disease for  years or more.
PHASE II: Previous or current invasive malignancies of other histologies requiring treatment within the last  years, with the exception of adequately treated basal cell or squamous cell carcinoma of the skin
Previous or concurrent malignancies at other sites within the last  years, with the exception of in situ carcinoma of the cervix and adequately treated basal cell carcinoma or squamous cell carcinoma of the skin; in addition, patients with prior or concomitant, based on hysterectomy, stage IA endometrial adenocarcinoma with less than  mm depth on invasion, absence of lymphovascular space invasion and absence of grade , papillary serous or clear cell histology are allowed
Current malignancies of another type, with the exception of adequately treated in situ cervical cancer, squamous cell and basal cell skin cancer or other malignancies with no evidence of disease for  years or more.
Previous or current malignancies of other histologies within the last  years, with the exception of cervical carcinoma in situ, adequately treated basal cell or squamous cell carcinoma of the skin, and treated low-risk prostate cancer
History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last  years.
Previous or current malignancies at other sites, with the exception of adequately treated in situ carcinoma of the cervix, basal or squamous cell carcinoma of the skin, thyroid cancer, or other cancer curatively treated by surgery and with no evidence of disease for at least  years
History of active malignancies other than chronic lymphocytic leukemia (CLL) within the past  years prior to study entry, with the exception of:\r\n* Adequately treated in situ carcinoma or the cervix or breast\r\n* Basal cell or localized squamous cell carcinoma of the skin\r\n* Previous malignancy treated with curative therapy and not expected to relapse
Serious autoimmune disease HLA SCREENING:  History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last  years MAIN SCREENING:
Previous or current malignancies of other histologies within the last  years, with the exception of in situ carcinoma of the cervix, and adequately treated basal cell or squamous cell carcinoma of the skin
Concomitant malignancies or previous malignancies within the last  years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
No previous or current malignancies at other sites within the last  years, with exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin
Patients must not have other invasive malignancies within the past  years (with the exception of adequately treated basal or squamous cell skin cancers, carcinoma in situ of the cervix and ductal carcinoma in situ [DCIS] of breast)
Previous or current malignancies of other histologies within the last  years, with the exception of in situ carcinoma of the cervix and adequately treated basal cell or squamous cell carcinoma of the skin
Concomitant malignancies or previous malignancies with less than a -year disease-free interval at the time of first dose of study treatment; patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or ductal carcinoma in situ may be enrolled irrespective of the time of diagnosis.
Previous or current malignancies at other sites, with the exception of adequately treated in situ carcinoma of the cervix, basal or squamous cell carcinoma of the skin, thyroid cancer, or other cancer curatively treated by surgery and with no current evidence of disease for at least  years
Concomitant malignancies or previous non-melanoma malignancies within the last  year, with the exception of adequately treated basal or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix
Active malignancies other than NSCLC within the last  years with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri or basal or squamous cell carcinoma of the skin
History of previous or current malignancy at other sites with the exception of adequately treated carcinoma in-situ of the cervix or basal or squamous cell carcinoma of the skin; patients with a history of other malignancies, who remain disease free for greater than five years are eligible
Current treatment, or treatment in the previous  months, for another non-melanoma malignancy, with the exception of adequately treated basal cell or squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ of the cervix; patients treated with curative intent for other malignancies within  months may be enrolled on a case by case basis after discussion/approval with the study PI
Part B: Current active malignancies of other types, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin. Prior cancer in remission for  years or more would not be excluded.
Previous or current malignancies of other histologies within the last  years (yrs) prior to randomization; with the exception of cervical cancer in situ, adequately treated basal cell or squamous cell carcinoma of skin or treated low risk prostate cancer
Current malignancies at other sites, with the exception of adequately treated basal or squamous cell carcinoma of the skin;
Concomitant malignancies or previous malignancies (other than multiple myeloma) with less than a -year disease-free interval at the time of first dose of study drug. Patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or Stage  prostate cancer are eligible irrespective of the time of diagnosis.
Concomitant malignancies or previous malignancies (other than multiple myeloma) with less than a -year disease-free interval at the time of first dose of study treatment. Patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or breast, or Stage  prostate cancer are eligible irrespective of the time of diagnosis.
Malignancies other than SCCHN within  years prior to enrollment, with the exception of adequately treated basal or squamous cell skin cancer and carcinoma in situ of the cervix or skin (e.g., melanoma in situ) or indolent prostate cancer
Concomitant malignancies or previous malignancies with less than a -year disease-free interval at the time of enrollment; patients with adequately resected basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix or ductal carcinoma in situ may enroll irrespective of the time of diagnosis.
Malignancies other than SCCHN within  years prior to randomization, with the exception of adequately treated basal or squamous cell skin cancer and carcinoma in situ of the cervix
History of previous or current malignancy at other sites with the exception of adequately treated carcinoma in-situ of the cervix or basal or squamous cell carcinoma of the skin; patients with a history of other malignancies, who remain disease free for greater than five years are eligible
Concomitant malignancies or previous malignancies within the last  years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix
No patients with history within the last  years of previous or current malignancy at other sites with the exception of adequately treated carcinoma in-situ of the cervix or basal or squamous cell carcinoma of the skin; patients with a history of other malignancies who remain disease free for greater than five years are eligible
Subjects with concomitant or previous malignancies within the last  years are excluded from the study; exceptions include: adequately treated basal or squamous cell carcinoma of the skin, carcinoma in situ of the cervix, and ductal carcinoma in situ (DCIS)
Systemic treatment for prior cancer within the last  years, with the exception of adequately treated cone-biopsied in situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin
Concomitant malignancies or previous malignancies with less than a -year disease free interval at the time of signing consent; patients with adequately resected basal or squamous cell carcinoma of the skin, or adequately resected carcinoma in situ (e.g. cervix) may enroll irrespective of the time of diagnosis
Patients with concomitant malignancies or previous malignancies within the last \n             years, with exception of adequately treated basal or squamous cell carcinoma of the\n             skin or carcinoma in situ of the cervix.
